These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1981623)

  • 21. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia.
    Glazer WM; Bowers MB; Charney DS; Heninger GR
    Biol Psychiatry; 1989 Jul; 26(3):224-33. PubMed ID: 2568132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study.
    Lomeña F; Catafau AM; Parellada E; Bernardo M; Font M; Gutiérrez F; Pavía J
    Psychopharmacology (Berl); 2004 Mar; 172(2):165-9. PubMed ID: 14624330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity.
    Freed WJ
    Schizophr Bull; 1988; 14(2):269-77. PubMed ID: 2904695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects.
    Wei J; Ramchand CN; Hemmings GP
    Schizophr Res; 1992 Dec; 8(2):103-10. PubMed ID: 1360811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients.
    Bessler H; Levental Z; Karp L; Modai I; Djaldetti M; Weizman A
    Biol Psychiatry; 1995 Sep; 38(5):297-302. PubMed ID: 7495923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
    Thaker GK; Wagman AM; Kirkpatrick B; Tamminga CA
    Biol Psychiatry; 1989 Jan; 25(1):75-86. PubMed ID: 2563233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Status-dependent neurochemical parameters in schizophrenic and affective diseases].
    Gross G; Huber G; Klosterkötter J; Rao ML; Linz M
    Fortschr Neurol Psychiatr; 1990 Apr; 58(4):154-60. PubMed ID: 1972372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C; Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical predictors of relapse following neuroleptic withdrawal.
    Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
    Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent concepts in clinical psychiatry: drug treatment in schizophrenia.
    Hussain SH
    J Pak Med Assoc; 1991 Sep; 41(9):229-34. PubMed ID: 1683911
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
    Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
    Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients.
    Meltzer HY; Duncavage MB; Jackman H; Arora RC; Tricou BJ; Young M
    Am J Psychiatry; 1982 Oct; 139(10):1242-8. PubMed ID: 6127035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.
    Laufer N; Spivak B; Holdengreber V; Zipser J; Kosower N; Ragolsky M; Weizman A
    Clin Neuropharmacol; 1999; 22(2):110-4. PubMed ID: 10202608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on neurochemical heterogeneity in healthy parents of schizophrenic patients.
    Wei J; Xu HM; Hemmings GP
    Schizophr Res; 1993 Aug; 10(2):173-8. PubMed ID: 8104469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Erythrocyte membrane transport of amino acid precursors of monoamines in schizophrenic patients. Comparison with depressive patients].
    Azorin JM; Bovier P; Widmer J; Tissot R; Jeanningros R
    Encephale; 1992; 18(5):585-90. PubMed ID: 1364121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.